EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardiovascular effects of tirzepatide

Priya Sumithran, Anthony W Russell, Sophia Zoungas iD

Journal of Endocrinology · 01.02.2025 · 264 (2)

DOI: 10.1530/joe-24-0259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, online erschienen am 03.01.2025. Verfasst von Priya Sumithran und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide is a first-in-class dual agonist at receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) for the treatment of T2D and obesity, with unprecedented efficacy for glycaemic control, reductions in body weight and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists. To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safety in high-risk patients. Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established. Several ongoing large-scale cardiovascular outcome trials for tirzepatide will provide a clearer understanding of where tirzepatide should be positioned in the treatment of established atherosclerotic cardiovascular disease or in people at high risk, in relation to current standard-of-care cardioprotective agents and approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCardiovascular SystemDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansTirzepatideGlucagon-Like Peptide 1ObesityGlucagon-Like Peptide-1 Receptor AgonistsAnimals

Stichwörter der Autor:innen

GIPGLP-1cardiovascular diseaseobesity medicationstirzepatide

Substanzen

TirzepatideGlucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

ORCID-Profile: Sophia Zoungas

Zitieren

APA

Sumithran, P., Russell, A. W., & Zoungas, S. (2025). Cardiovascular effects of tirzepatide. Journal of Endocrinology, 264(2). https://doi.org/10.1530/joe-24-0259

Vancouver

Sumithran P, Russell AW, Zoungas S. Cardiovascular effects of tirzepatide. Journal of Endocrinology. 2025;264(2). doi:10.1530/joe-24-0259

BibTeX
@article{Sumithran2025,
  author = {Sumithran, Priya and Russell, Anthony W and Zoungas, Sophia},
  title = {Cardiovascular effects of tirzepatide},
  journal = {Journal of Endocrinology},
  year = {2025},
  volume = {264},
  number = {2},
  doi = {10.1530/joe-24-0259}
}
Kostenlos starten →